Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manige Konig

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Diabetes, Obesity & Metabolism|October 26, 2021
A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutideLai San Tham, Kevin M Pantalone, Kathleen Dungan, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 12, 2020
Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature ReviewSusan Robinson, Kristina S Boye, Reema Mody, et al.
Kidney360|April 4, 2022
Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory AnalysisKatherine R Tuttle, Brian Rayner, Mark C Lakshmanan, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 1, 2024
Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World StudyMeredith Hoog, Juan M Maldonado, Ruth Wangia-Dixon, et al.
Diabetes, Obesity & Metabolism|August 4, 2020
Cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists: A comparison of study designs, populations and resultsKevin M Pantalone, Kashif Munir, Clinton M Hasenour, et al.
Diabetes, Obesity & Metabolism|May 12, 2022
Examining the evidence for weight management in individuals with type 2 diabetesW Timothy Garvey, Guillermo E Umpierrez, Julia P Dunn, et al.
Cardiovascular Diabetology|March 10, 2023
General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trialEdward Franek, Prem Pais, Jan Basile, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 13, 2021
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11Joanna Van, Juan P Frias, Enzo Bonora, et al.
Diabetes, Obesity & Metabolism|June 23, 2021
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trialJuan P Frias, Enzo Bonora, Luis Nevárez Ruiz, et al.
Diabetes, Obesity & Metabolism|August 14, 2025
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetesJulio Rosenstock, Deborah A Robins, Kevin L Duffin, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Diabetes, Obesity & Metabolism|October 26, 2021
A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutideLai San Tham, Kevin M Pantalone, Kathleen Dungan, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 12, 2020
Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature ReviewSusan Robinson, Kristina S Boye, Reema Mody, et al.
Kidney360|April 4, 2022
Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory AnalysisKatherine R Tuttle, Brian Rayner, Mark C Lakshmanan, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 1, 2024
Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World StudyMeredith Hoog, Juan M Maldonado, Ruth Wangia-Dixon, et al.
Diabetes, Obesity & Metabolism|August 4, 2020
Cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists: A comparison of study designs, populations and resultsKevin M Pantalone, Kashif Munir, Clinton M Hasenour, et al.
Diabetes, Obesity & Metabolism|May 12, 2022
Examining the evidence for weight management in individuals with type 2 diabetesW Timothy Garvey, Guillermo E Umpierrez, Julia P Dunn, et al.
Cardiovascular Diabetology|March 10, 2023
General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trialEdward Franek, Prem Pais, Jan Basile, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 13, 2021
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11Joanna Van, Juan P Frias, Enzo Bonora, et al.
Diabetes, Obesity & Metabolism|June 23, 2021
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trialJuan P Frias, Enzo Bonora, Luis Nevárez Ruiz, et al.
Diabetes, Obesity & Metabolism|August 14, 2025
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetesJulio Rosenstock, Deborah A Robins, Kevin L Duffin, et al.
Pageof 3